Raymond James Financial Services Advisors Inc. Trims Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Raymond James Financial Services Advisors Inc. decreased its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 11.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,845 shares of the medical device company’s stock after selling 1,950 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Tandem Diabetes Care were worth $469,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. State of Wyoming lifted its position in Tandem Diabetes Care by 45.8% during the fourth quarter. State of Wyoming now owns 821 shares of the medical device company’s stock worth $37,000 after buying an additional 258 shares in the last quarter. RiverPark Advisors LLC acquired a new stake in Tandem Diabetes Care during the fourth quarter worth $27,000. Stephens Inc. AR increased its stake in Tandem Diabetes Care by 17.6% during the first quarter. Stephens Inc. AR now owns 2,120 shares of the medical device company’s stock worth $86,000 after acquiring an additional 317 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in Tandem Diabetes Care during the first quarter worth $256,000. Finally, Lazard Asset Management LLC increased its stake in Tandem Diabetes Care by 174.5% during the first quarter. Lazard Asset Management LLC now owns 2,616 shares of the medical device company’s stock worth $304,000 after acquiring an additional 1,663 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have issued reports on TNDM. StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday. Stifel Nicolaus raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and raised their target price for the stock from $24.00 to $37.00 in a research note on Tuesday, March 26th. Finally, Citigroup raised their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $37.00.

Tandem Diabetes Care Trading Down 1.6 %

NASDAQ:TNDM opened at $30.43 on Friday. The firm has a market cap of $1.96 billion, a PE ratio of -8.85 and a beta of 1.12. The stock has a fifty day moving average price of $29.80 and a 200 day moving average price of $24.80. Tandem Diabetes Care, Inc. has a 12-month low of $13.82 and a 12-month high of $40.92. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $196.80 million during the quarter, compared to analysts’ expectations of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. Sell-side analysts anticipate that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.